ALKS Alkermes plc

NASDAQ
$46.85

Alkermes plc (ALKS) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Subdued Selling ran below ALKS's own trailing one-year pace, with 100% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 2 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
2
4 transactions
Purchases
$0
0 shares
Sales
$697.9K
15,103 shares
Net activity
-$697.9K
purchases less sales

How much of that selling was preplanned? 100% planned / 0% discretionary

10b5-1 plan sales $697.9K 4 transactions · 15,103 shares
Discretionary sales $0 0 transactions · 0 shares

Largest single sale: $422.9K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 10b5-1 2,035 $46.17 $94.0K 219,353 −0.9% of holding
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 10b5-1 2,034 $41.03 $83.5K 221,388 −0.9% of holding
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 10b5-1 2,034 $48.01 $97.7K 223,422 −0.9% of holding
Hopkinson Craig C. EVP R&D, Chief Medical Officer Sell 10b5-1 9,000 $46.99 $422.9K 65,389 −12.1% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.